Color enhancement: Difference between revisions

Line 1:

'''Color enhancement''' can be described as the experience of colors becoming extremely bright or vivid and standing out.<ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref> During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref>Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753</ref><ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref>

'''Color enhancement''' can be described as the experience of colors becoming extremely bright or vivid and standing out.<ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref>Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753</ref><ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref>

Studies have also suggested an accompanying effect of decreased hue discrimination resulting in anecdotal accounts of percieving colours which are seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>

@@ Line 1: / Line 1: @@
 <onlyinclude>
-'''Color enhancement''' can be described as the experience of colors becoming extremely bright or vivid and standing out.<ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref> During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref>Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753</ref><ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref>
+'''Color enhancement''' can be described as the experience of colors becoming extremely bright or vivid and standing out.<ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref>Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753</ref><ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref>
 Studies have also suggested an accompanying effect of decreased hue discrimination resulting in anecdotal accounts of percieving colours which are seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>